Cold Chain Logistics: Safeguarding Comparator Integrity in Clinical Trials

Cold-chain logistics play a pivotal role in pharmaceutical supply, ensuring patient safety and trial continuity. This is especially true in the oncology sector, where most therapies are temperature-sensitive and in high demand, amplifying the need for robust cold-chain infrastructure.

Cold-chain logistics refers to the temperature-controlled transport and storage of pharmaceutical products. For biologics, cell and gene therapies and many oncology medications, maintaining a narrow temperature range, from manufacturing to administration at clinical sites is essential to preserve drug efficacy and stability. Any break in the cold chain can compromise the product, leading to wastage, and, more critically, harm to patients or invalid trial results.

CSI has completed more than half a million cold chain shipments, combining expertise in global regulatory frameworks with direct manufacturer relationships and GDP-certified cold-chain capabilities. CSI is a proven leader in the procurement and delivery of comparator drugs, even in constrained supply environments, whilst maintaining compliance with temperature and handling protocols.

Cold-chain logistics is a complex balance involving real-time monitoring, validated packaging, route risk assessments and contingency planning. Partnering with a supply provider that can navigate these complexities is crucial to preventing costly trial delays and wastage.

Sustainability is also becoming a key consideration in cold-chain planning. Reducing the environmental footprint of temperature-controlled shipments is a growing challenge that demands innovation across packaging, routing and technology. Clinical Services International (CSI) has been awarded the EcoVadis Platinum Award for the second year in a row, highlighting its commitment to sustainable procurement and responsible supply chain practices.